Novo-Nordisk A/S (NVO) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and m...
Novo-Nordisk A/S (NVO) currently trades at a P/E ratio of 1.99 (historical range: 1.92–2.24, median: 2.04), placing it at the 14th percentile — cheap relative to its history, P/S ratio of 0.66 (range: 0.64–0.74, 14th percentile — cheap relative to its history), EV/EBITDA of 2.41 (range: 2.36–2.61, 14th percentile).
Novo-Nordisk A/S appears significantly undervalued relative to its historical range, trading at depressed multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 1.99 | 1.92 | 2.04 | 2.24 | 14th | cheap relative to its history |
| P/S Ratio | 0.66 | 0.64 | 0.68 | 0.74 | 14th | cheap relative to its history |
| EV/EBITDA | 2.41 | 2.36 | 2.45 | 2.61 | 14th | cheap relative to its history |